nach oben

NeuroMolecular Medicine

Erschienen in:

01.09.2009 | Original Paper

The Therapeutic Potential of microRNAs in Nervous System Damage, Degeneration, and Repair

verfasst von: Emmette R. Hutchison, Eitan Okun, Mark P. Mattson

Erschienen in: NeuroMolecular Medicine | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

MicroRNAS (miRNAs) have been suggested to play important roles in the central nervous system during development as well as disease. miRNAs appear to be dysregulated in a number of neurodegenerative diseases, developmental disorders, and as a result of stroke. Each miRNA has the ability to regulate hundreds of messenger RNA transcripts, both by causing degradation of the mRNA and by inhibition of protein translation. Recent findings suggest that it may eventually be possible to treat some neurological disorders by restoring or inhibiting miRNAs altered by disease pathology. Both viral delivery and administration of modified oligonucleotides mimicking or inhibiting specific miRNAs have been effective in model systems. Artificial miRNAs have also been generated for the repression of specific transcripts. Alteration of miRNA expression by disease and insult also holds the potential for improved diagnostic tools. Finally, miRNAs have been shown to control cellular proliferation and specification, suggesting that manipulation of miRNAs in cultured cells could result in more convenient generation of pure cell populations for transplantation.

Abelson, J. F., Kwan, K. Y., O’Roak, B. J., Baek, D. Y., Stillman, A. A., Morgan, T. M., et al. (2005). Sequence variants in SLITRK1 are associated with Tourette’s syndrome. Science, 310(5746), 317–320.CrossRefPubMed

Baek, D., Villén, J., Shin, C., Camargo, F. D., Gygi, S. P., & Bartel, D. P. (2008). The impact of microRNAs on protein output. Nature, 455(7209), 64–71.CrossRefPubMed

Beveridge, N. J., Tooney, P. A., Carroll, A. P., Gardiner, E., Bowden, N., Scott, R. J., et al. (2008). Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Human Molecular Genetics, 17(8), 1156–1168.CrossRefPubMed

Boissonneault, V., Plante, I., Rivest, S., & Provost, P. (2009). MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1. Journal of Biological Chemistry, 284(4), 1971–1981.CrossRefPubMed

Boudreau, R. L., Martins, I., & Davidson, B. L. (2009). Artificial microRNAs as siRNA shuttles: Improved safety as compared to shRNAs in vitro and in vivo. Molecular Therapy, 17(1), 169–175.CrossRefPubMed

Burmistrova, O. A., Goltsov, A. Y., Abramova, L. I., Kaleda, V. G., Orlova, V. A., & Rogaev, E. I. (2007). MicroRNA in schizophrenia: Genetic and expression analysis of miR-130b (22q11). Biochemistry (Mosc), 72(5), 578–582.CrossRef

Cao, X., Pfaff, S. L., & Gage, F. H. (2007). A functional study of miR-124 in the developing neural tube. Genes and Development, 21(5), 531–536.CrossRefPubMed

Carthew, R. W., & Sontheimer, E. J. (2009). Origins and Mechanisms of miRNAs and siRNAs. Cell, 136, 642–655.CrossRefPubMed

Castanotto, D., Sakurai, K., Lingeman, R., Li, H., Shively, L., Aagaard, L., et al. (2007). Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Research, 35(15), 5154–5164.CrossRefPubMed

Cataldo, A. M., Petanceska, S., Peterhoff, C. M., Terio, N. B., Epstein, C. J., Villar, A., et al. (2003). App gene dosage modulates endosomal abnormalities of Alzheimer’s disease in a segmental trisomy 16 mouse model of down syndrome. Journal of Neuroscience, 23, 6788–6792.PubMed

Cockrell, A. S., & Kafri, T. (2007). Gene delivery by lentivirus vectors. Molecular Biotechnology, 36, 184–204.CrossRefPubMed

Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., et al. (2008). Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. Journal of Alzheimer’s Disease, 14(1), 27–41.PubMed

Conaco, C., Otto, S., Han, J. J., & Mandel, G. (2006). Reciprocal actions of REST and a microRNA promote neuronal identity. Proceedings of the National Academy of Sciences of the United States of America, 103(7), 2422–2427.CrossRefPubMed

Croce, C. M., & Calin, G. A. (2005). miRNAs, cancer, and stem cell division. Cell, 122(1), 6–7.CrossRefPubMed

De Pietri Tonelli, D., Pulvers, J. N., Haffner, C., Murchison, E. P., Hannon, G. J., & Huttner, W. B. (2008). miRNAs are essential for survival and differentiation of newborn neurons but not for expansion of neural progenitors during early neurogenesis in the mouse embryonic neocortex. Development, 135, 3911–3921.CrossRefPubMed

Dharap, A., Bowen, K., Place, R., Li, L. C., & Vemuganti, R. (2009). Transient focal ischemia induces extensive temporal changes in rat cerebral microRNAome. Journal of Cerebral Blood Flow and Metabolism, 29(4), 675–687.CrossRefPubMed

Ebert, M. S., Neilson, J. R., & Sharp, P. A. (2007). MicroRNA sponges: Competitive inhibitors of small RNAs in mammalian cells. Nature Methods, 4(9), 721–726.CrossRefPubMed

Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., et al. (2008a). LNA-mediated microRNA silencing in non-human primates. Nature, 452, 896–899.CrossRefPubMed

Elmén, J., Lindow, M., Silahtaroglu, A., Bak, M., Christensen, M., Lind-Thomsen, A., et al. (2008b). Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Research, 36, 1153–1162.CrossRefPubMed

Faghihi, M. A., Modarresi, F., Khalil, A. M., Wood, D. E., Sahagan, B. G., Morgan, T. E., et al. (2008). Expression of a noncoding RNA is elevated in Alzheimer’s disease and drives rapid feed-forward regulation of beta-secretase. Nature Medicine, 14(7), 723–730.CrossRefPubMed

Gonzalez-Alegre, P., Bode, N., Davidson, B. L., & Paulson, H. L. (2005). Silencing primary dystonia: Lentiviral-mediated RNA interference therapy for DYT1 dystonia. Journal of Neuroscience, 25, 10502–10509.CrossRefPubMed

Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., et al. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature, 441(7092), 537–541.CrossRefPubMed

Harper, S. Q., & Gonzalez-Alegre, P. (2008). Lentivirus-mediated RNA interference in mammalian neurons. Methods in Molecular Biology, 442, 95–112.CrossRefPubMed

Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., et al. (2008). Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/beta-secretase expression. Proceedings of the National Academy of Sciences of the United States of America, 105(17), 6415–6420.CrossRefPubMed

Hol, E. M., van Leeuwen, F. W., & Fischer, D. F. (2005). The proteasome in Alzheimer’s disease and Parkinson’s disease: Lessons from ubiquitin B+1. Trends in Molecular Medicine, 11, 488–495.PubMed

Jeyaseelan, K., Lim, K. Y., & Armugam, A. (2008). MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion. Stroke, 39(3), 959–966.CrossRefPubMed

Johnson, R., Zuccato, C., Belyaev, N. D., Guest, D. J., Cattaneo, E., & Buckley, N. J. (2008). A microRNA-based gene dysregulation pathway in Huntington’s disease. Neurobiology of Diseases, 29(3), 438–445.CrossRef

Kapsimali, M., Kloosterman, W. P., de Bruijn, E., Rosa, F., Plasterk, R. H., & Wilson, S. W. (2007). MicroRNAs show a wide diversity of expression profiles in the developing and mature central nervous system. Genome Biology, 8(8), R173.CrossRefPubMed

Keller, J. N., Hanni, K. B., & Markesbery, W. R. (2000). Impaired proteasome function in Alzheimer’s disease. Journal of Neurochemistry, 75, 436–439.CrossRefPubMed

Kim, J., Inoue, K., Ishii, J., Vanti, W. B., Voronov, S. V., Murchison, E., et al. (2007). A MicroRNA feedback circuit in midbrain dopamine neurons. Science, 317(5842), 1220–1224.CrossRefPubMed

Krichevsky, A. M., Sonntag, K. C., Isacson, O., & Kosik, K. S. (2006). Specific microRNAs modulate embryonic stem cell-derived neurogenesis. Stem Cells, 24, 857–864.CrossRefPubMed

Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., et al. (2005). Silencing of microRNAs in vivo with ‘antagomirs’. Nature, 438(7068), 685–689.CrossRefPubMed

Kumar, P., Wu, H., McBride, J. L., Jung, K. E., Kim, M. H., Davidson, B. L., et al. (2007). Transvascular delivery of small interfering RNA to the central nervous system. Nature, 448(7149), 39–43.CrossRefPubMed

Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75, 843–854.CrossRefPubMed

Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., et al. (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature, 433(7027), 769–773.CrossRefPubMed

Lukiw, W. J., Zhao, Y., & Cui, J. G. (2008). An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. Journal of Biological Chemistry, 283(46), 31315–31322.CrossRefPubMed

Makeyev, E. V., et al. (2007). The microRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Molecular Cell, 27, 435–448.CrossRefPubMed

Mattson, M. P. (2004). Pathways towards and away from Alzheimer’s disease. Nature, 430(7000), 631–639.CrossRefPubMed

Mattson, M. P., Maudsley, S., & Martin, B. (2004). BDNF and 5-HT: A dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends in Neurosciences, 27(10), 589–594.CrossRefPubMed

McBride, J. L., Boudreau, R. L., Harper, S. Q., Staber, P. D., Monteys, A. M., Martins, I., et al. (2008). Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi. Proceedings of the National Academy of Sciences of the United States of America, 105(15), 5868–5873.CrossRefPubMed

Mellios, N., Huang, H. S., Grigorenko, A., Rogaev, E., & Akbarian, S. (2008). A set of differentially expressed miRNAs, including miR-30a–5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex. Human Molecular Genetics, 17(19), 3030–3042.CrossRefPubMed

Miska, E. A., Alvarez-Saavedra, E., Townsend, M., Yoshii, A., Sestan, N., Rakic, P., et al. (2004). Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biology, 5(9):R68.CrossRefPubMed

Packer, A. N., Xing, Y., Harper, S. Q., Jones, L., & Davidson, B. L. (2008). The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington’s disease. Journal of Neuroscience, 28(53), 14341–14346.CrossRefPubMed

Perkins, D. O., Jeffries, C. D., Jarskog, L. F., Thomson, J. M., Woods, K., Newman, M. A., et al. (2007). microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biology, 8(2), R27.CrossRefPubMed

Redell, J. B., Liu, Y., & Dash, P. K. (2009). Traumatic brain injury alters expression of hippocampal microRNAs: Potential regulators of multiple pathophysiological processes. Journal of Neuroscience Research, 87(6), 1435–1448.CrossRefPubMed

Ren, G., Li, T., Lan, J. Q., Wilz, A., Simon, R. P., & Boison, D. (2007). Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: A novel perspective for seizure control. Experimental Neurology, 208(1), 26–37.CrossRefPubMed

Saba, R., Goodman, C. D., Huzarewich, R. L., Robertson, C., & Booth, S. A. (2008). A miRNA signature of prion induced neurodegeneration. PLoS ONE, 3(11), e3652.CrossRefPubMed

Salehi, A., Delcroix, J. D., Belichenko, P. V., Zhan, K., Wu, C., Valletta, J. S., et al. (2006). Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron, 51, 29–42.CrossRefPubMed

Sapru, M. K., Yates, J. W., Hogan, S., Jiang, L., Halter, J., & Bohn, M. C. (2006). Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Experimental Neurology, 198, 382–390.CrossRefPubMed

Schwamborn, J. C., Berezikov, E., & Knoblich, J. A. (2009). The TRIM-NHL protein TRIM32 activates microRNAs and prevents self-renewal in mouse neural progenitors. Cell, 136(5), 913–925.CrossRefPubMed

Selbach, M., Schwanhäusser, B., Thierfelder, N., Fang, Z., Khanin, R., & Rajewsky, N. (2008). Widespread changes in protein synthesis induced by microRNAs. Nature, 455(7209), 58–63.CrossRefPubMed

Sempere, L. F., Freemantle, S., Pitha-Rowe, I., Moss, E., Dmitrovsky, E., & Ambros, V. (2004). Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biology, 5(3):R13.CrossRefPubMed

Sheedy, F. J., & O’Neill, L. A. (2008). Adding fuel to fire: microRNAs as a new class of mediators of inflammation. Annals of the Rheumatic Diseases, 67(Suppl 3), iii50–iii55.CrossRefPubMed

Silahtaroglu, A. N., Nolting, D., Dyrskjøt, L., Berezikov, E., Møller, M., Tommerup, N., et al. (2007). Detection of microRNAs in frozen tissue sections by fluorescence in situ hybridization using locked nucleic acid probes and tyramide signal amplification. Nature Protocols, 2(10), 2520–2528.CrossRefPubMed

Singer, O., Marr, R. A., Rockenstein, E., Crews, L., Coufal, N. G., Gage, F. H., et al. (2005). Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nature Neuroscience, 8(10), 1343–1349.CrossRefPubMed

Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., et al. (2003). alpha-Synuclein locus triplication causes Parkinson’s disease. Science, 302, 841.CrossRefPubMed

Singleton, A., Myers, A., & Hardy, J. (2004). The law of mass action applied to neurodegenerative disease: A hypothesis concerning the etiology and pathogenesis of complex diseases. Human and Molecular Genetics, 13(Spec No 1), R123–R126.CrossRef

Smirnova, L., Gräfe, A., Seiler, A., Schumacher, S., Nitsch, R., & Wulczyn, F. G. (2005). Regulation of miRNA expression during neural cell specification. European Journal of Neuroscience, 21(6), 1469–1477.CrossRefPubMed

Tsang, J., Zhu, J., & van Oudenaarden, A. (2007). MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Molecular Cell, 26(5), 753–767.CrossRefPubMed

Urbich, C., Kuehbacher, A., & Dimmeler, S. (2008). Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovascular Research, 79(4), 581–588.CrossRefPubMed

van Solingen, C., Seghers, L., Bijkerk, R., Duijs, J. M., Roeten, M. K., van Oeveren-Rietdijk, A. M., et al. (2008). Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. Journal of Cellular and Molecular Medicine. 2008 Dec 16. [Epub ahead of print].

Várallyay, E., Burgyán, J., & Havelda, Z. (2008). MicroRNA detection by northern blotting using locked nucleic acid probes. Nature Protocols, 3(2), 190–196.CrossRefPubMed

Wang, W. X., Rajeev, B. W., Stromberg, A. J., Ren, N., Tang, G., Huang, Q., et al. (2008a). The expression of microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. Journal of Neuroscience, 28, 1213–1223.CrossRefPubMed

Wang, G., van der Walt, J. M., Mayhew, G., Li, Y. J., Züchner, S., Scott, W. K., et al. (2008b). Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. American Journal of Human Genetics, 82, 283–289.CrossRefPubMed

Zhao, C., Deng, W., & Gage, F. H. (2008). Mechanisms and functional implications of adult neurogenesis. Cell, 132(4), 645–660.CrossRefPubMed

Zhao, C., Sun, G., Li, S., & Shi, Y. (2009). A feedback regulatory loop involving microRNA-9 and nuclear receptor TLX in neural stem cell fate determination. Nature Structural & Molecular Biology, 16(4), 365–371.CrossRef

Zhou, R., Yuan. P., Wang, Y., Hunsberger, J. G., Elkahloun, A., Wei, Y., et al. (2009). Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology, 34, 1395–1405.CrossRefPubMed

Zuccato, C., Belyaev, N., Conforti, P., Ooi, L., Tartari, M., Papadimou, E., et al. (2007). Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. Journal of Neuroscience, 27, 6972–6983.CrossRefPubMed

Titel: The Therapeutic Potential of microRNAs in Nervous System Damage, Degeneration, and Repair
verfasst von: Emmette R. Hutchison
Eitan Okun
Mark P. Mattson
Publikationsdatum: 01.09.2009
Verlag: Humana Press Inc
Erschienen in: NeuroMolecular Medicine / Ausgabe 3/2009
Print ISSN: 1535-1084
Elektronische ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-009-8086-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

microRNAs in Gliomas: Small Regulators of a Big Problem

microRNA Regulation of Synaptic Plasticity

Macro Role(s) of MicroRNAs in Fragile X Syndrome?

microRNAs in CNS Disorders

MicroRNAs in Mental Health: From Biological Underpinnings to Potential Therapies